Page 2441 - Williams Hematology ( PDFDrive )

2412 Index Index 2413

CD49f/CD29. See Integrin α β CD109, 1871 C/EBPε, 926, 1011
6 1
CD 50, 1184 CD110. See Thrombopoietin (TPO) receptor Cefepime, 384, 385, 387t
CD51/CD61. See Integrin α β (c-mpl, CD110) Ceftaroline, 384
v 3
CD 52, 1535 CD117, 260, 974, 1380t, 1393 Ceftazidime, 384, 385, 387t
CD 52-targeting antibody. See Alemtuzumab CD123, 1393 Ceftobiprole, 385
CD54. See ICAM-1 (CD54) CD133, 260 Celecoxib, 2075, 2121
CD55, 572, 1053f, 1871 CD135 (Flt3), 309 Celiac disease, 597, 630, 1575
CD56 (NCAM), 1142, 1189, 1699, 1726, 1737 CD138 (syndecan 1), 1141, 1712, 1714, 1737 Cell adhesion, 65–68, 67t
CD56 bright NK cells, 93, 1189 CD142. See Tissue factor (TF) BCR-ABL1 and, 1440–1441
CD57 (LEU7), 1528 CD143, 1144t in sickle cell disease, 764–765
CD58 (LFA-3), 1184, 1185, 1978 CD144, 68 Cell cycle
CD59, 572, 1053f, 1285, 1871, 2358 CD148, 1172 cancer chemotherapy and, 317
CD59 blood group, 2333t CD151, 1871 regulation, 213–241, 214f
CD61, 1184 CD152 (CTLA-4), 424, 1184 checkpoints, 218–219
CD62E. See E-selectin CD154. See CD40 ligand (CD40L, CD154) cyclins and cyclin-dependent kinases,
CD62L. See L-selectin CD156a, 1144t 213–218, 215t, 217f
CD62L+ cells (memory stem cells), 411 CD156b, 1144t histone deacetylases, 239–240, 239t,
CD62P. See P-selectin CD157, 1144t 240f
CD63, 1009, 1011, 1013, 1836, 1871 CD163, 499, 1061, 1080 oncogenes, 219–222
CD64. See Fcγ receptor I (FCγRI, CD64) CD164, 260 proteasome, 240–241
CD65, 1380t, 1383, 1512 CD178, 1564 tumor-suppressor genes, 237–239
CD66, 1014 CD200, 1084 Cell cycle-active antineoplastic agents,
CD68, 1013 CD-209 (DC-SIGN), 308, 1057t, 1082 329–331
CD69, 948 CD224, 1144t Cell dehydration, in sickle cell disease, 764
CD70, 1788 CD244, 949 Cell fusion, 269
CD72, 1163 CD247, 1177 Cell growth and metabolism
CD73, 1144t, 1834, 1971, 1972f CD278 (iCOS), 1184 gene expression and, 196
CD79, 1785 CD279 (PDCD1), 1184 in hematopoietic stem cells, 196–197, 197f
CD79a (Ig-α) 2-CDA. See Cladribine homeostasis, 191
in Burkitt lymphoma, 1674 CDAN1, 565 in leukemias, 197–198, 199f
in diffuse large B-cell lymphoma, 1627 CDAs. See Congenital dyserythropoietic in lymphomas, 199–200
in extranodal marginal zone lymphoma, anemias (CDAs) in myeloma, 200–201
1665 Cdc42, 309, 1841, 1883 signaling and nutrients, 191–192
in follicular lymphoma, 1642 CDDO-Me, 1403 signal transduction and, 193–196, 194f,
immunoglobulin M and, 1162, 1162f CDK4, 1653 195f
in precursor B cells, 1168 CDKIs (cyclin-dependent kinase inhibitors), Cell homing, 68–71
in primary mediastinal large B-cell 217–218, 1539 Cell-mediated cytotoxicity, 1190–1191, 1190f
lymphoma, 1634 CDKN1B, 234t Cell proliferation gene signature, 1654
CD79B, 233t, 236t CDKN2 (p16), 232t, 236t, 1654, 1734 Cell signaling. See Signal transduction
CD79b (Ig-β), 1162, 1162f, 1168 CDKN2A/B, 177f, 1508 pathways
CD80, 1183, 1184, 1185f CDKN2c, 234t Cell-surface proteins, 487
CD86 cdks. See under Cyclin-dependent kinase Cellular immunity, newborn, 108
in dendritic cell maturation, 309 (cdk) Cellular senescence, 132
in T-cell interactions, 1183, 1184, 1185f CDRs (complementarity determining Cellular therapy. See Immune cell therapy
CD87, 2358 region), 1170 (adoptive cellular therapy)
CD89, 1008 CDw32 (FcγRII), 953 Central nervous system. See also Neurologic
CD90, 260 ceAML (clonally evolved acute myelogenous disease/symptoms
CD94, 1190 leukemia), 1281 leukemia, 1510, 1515, 1516, 1518
CD95. See Fas (CD95) C/EBPA (CEBPA, CEPBα) macrophages, 1083
CD97, 1059 in acute myelogenous leukemia, 181, 181t, microglia, 1083
CD99, 1977t, 1978 182, 226t, 363, 1378t, 1379 primary lymphoma, 1244f, 1246, 1579
CD102. See ICAM-2 (CD102) in myelodysplastic syndromes, 181t, 1345, Central venous catheter placement, bleeding
CD106. See Vascular cell adhesion molecule 1351 risk and, 2384
(VCAM)-1 CEBPB, 1699 Centromere, 175t
CD107a (LAMP-1), 1873 C/EBP homologous protein (CHOP), 204f, CEP. See Congenital erythropoietic porphyria
CD107b (LAMP-2), 1873 205, 208f (CEP)

Kaushansky_index_p2393-2506.indd 2412 9/21/15 3:21 PM